Raloxifene News and Research

RSS
Raloxifene is an oral selective estrogen receptor modulator (SERM) that has oestrogenic actions on bone and anti-oestrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.
The effect of Raloxifene treatment in postmenopausal women with chronic kidney disease

The effect of Raloxifene treatment in postmenopausal women with chronic kidney disease

Value of drugs for pre-osteoporosis exaggerated

Value of drugs for pre-osteoporosis exaggerated

Effectiveness and risks of six bisphosphonates for osteoporosis

Effectiveness and risks of six bisphosphonates for osteoporosis

Evista (raloxifene hydrochloride) approved for breast cancer

Evista (raloxifene hydrochloride) approved for breast cancer

Breast cancer prevention practices vary across Canada

Breast cancer prevention practices vary across Canada

Sex and gender in cardiovascular-renal physiology and pathophysiology

Sex and gender in cardiovascular-renal physiology and pathophysiology

FDA panel will help decide fate of drug Evista for preventing breast cancer

FDA panel will help decide fate of drug Evista for preventing breast cancer

Health care professionals should focus on women's lifetime heart disease risk

Health care professionals should focus on women's lifetime heart disease risk

An aspirin a day keeps heart disease away

An aspirin a day keeps heart disease away

Updated guidelines provide definitive answers on HRT, aspirin, supplements

Updated guidelines provide definitive answers on HRT, aspirin, supplements

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

Raloxifene reduces breast cancer risk in postmenopausal women

Raloxifene reduces breast cancer risk in postmenopausal women

Hormonal treatments reduce risk of cancer returning

Hormonal treatments reduce risk of cancer returning

Osteoporosis drug Raloxifene shown to be as effective as Tamoxifen in preventing invasive breast cancer

Osteoporosis drug Raloxifene shown to be as effective as Tamoxifen in preventing invasive breast cancer

Researchers release results of (STAR) breast cancer prevention trial

Researchers release results of (STAR) breast cancer prevention trial

Evista may be a better option than Tamoxifen for reducing breast cancer risk

Evista may be a better option than Tamoxifen for reducing breast cancer risk

Raloxifene shows potential benefits in treating prostate cancer

Raloxifene shows potential benefits in treating prostate cancer

Tamoxifen reduces long-term risk of cancer

Tamoxifen reduces long-term risk of cancer

Osteoporosis drug reduces women's risk of mild cognitive impairment

Osteoporosis drug reduces women's risk of mild cognitive impairment

Calcium crucial to benefits of osteoporosis drugs

Calcium crucial to benefits of osteoporosis drugs